The Phase 2 trial, called ANDROMEDA, is the first study to directly compare two types of PSMA-targeted radiopharmaceuticals when used alongside stereotactic body radiotherapy (SBRT), a focused form of ...

Patients with PSMA-positive metastatic castration-resistant prostate cancer can now be treated with Pluvicto, which may provide hope to an unmet need in this patient population. The Food and Drug ...

University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.” The conference will take place online and ...

A panel of experts offers guidance for selecting patients with mCRPC for treatment with 177Lu-PSMA-617 and for managing treatment-related toxicities. The treatment is approved for use in men with ...

Figure 1. A 74-y-old man at initial staging with PSMA PET that demonstrates low uptake in primary tumor (A, arrowhead) and left pelvic side wall node (A, arrow). Bone scan was read as positive by 2 of ...